{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:51:03Z","timestamp":1790398263994,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["AI116635"],"award-info":[{"award-number":["AI116635"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.antiviral.2016.12.003","type":"journal-article","created":{"date-parts":[[2016,12,8]],"date-time":"2016-12-08T09:47:02Z","timestamp":1481190422000},"page":"57-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene"],"prefix":"10.1016","volume":"138","author":[{"given":"Sunwen","family":"Chou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2016.12.003_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.antiviral.2016.02.004","article-title":"Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: benefits and limits of 3D analysis","volume":"129","author":"Andouard","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2016.12.003_bib2","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/TP.0000000000001418","article-title":"Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection","volume":"100","author":"Avery","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.antiviral.2016.12.003_bib3","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1586\/eri.12.115","article-title":"Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients","volume":"10","author":"Bacigalupo","year":"2012","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.antiviral.2016.12.003_bib4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/rmv.1873","article-title":"Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art","volume":"26","author":"Campos","year":"2016","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2016.12.003_bib5","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1128\/AAC.00259-10","article-title":"Differentiation between polymorphisms and resistance associated mutations in the human cytomegalovirus DNA polymerase","volume":"54","author":"Chevillotte","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.12.003_bib6","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/AAC.00186-10","article-title":"Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance","volume":"54","author":"Chou","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.12.003_bib7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jcv.2011.01.004","article-title":"Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy","volume":"50","author":"Chou","year":"2011","journal-title":"J.\u00a0Clin. Virol."},{"key":"10.1016\/j.antiviral.2016.12.003_bib8","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid in\u00a0vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.12.003_bib9","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1093\/infdis\/jit654","article-title":"Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial","volume":"209","author":"Chou","year":"2014","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.12.003_bib10","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1128\/AAC.00214-16","article-title":"Novel cytomegalovirus UL54 DNA polymerase gene mutations selected in\u00a0vitro that confer brincidofovir resistance","volume":"60","author":"Chou","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.12.003_bib11","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1128\/AAC.49.7.2710-2715.2005","article-title":"Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene","volume":"49","author":"Chou","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.12.003_bib12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1177\/135965350601100416","article-title":"A\u00a0novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet","volume":"11","author":"Ducancelle","year":"2006","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2016.12.003_bib13","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1128\/AAC.00334-11","article-title":"Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet","volume":"55","author":"Gilbert","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.12.003_bib14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/tid.12241","article-title":"Cytomegalovirus antiviral resistance: characterization of results from clinical specimens","volume":"16","author":"Kleiboeker","year":"2014","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.12.003_bib15","doi-asserted-by":"crossref","first-page":"18193","DOI":"10.1074\/jbc.M602414200","article-title":"Crystal structure of the herpes simplex virus 1 DNA polymerase","volume":"281","author":"Liu","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.antiviral.2016.12.003_bib16","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2016.12.003_bib17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1386-6532(02)00046-X","article-title":"Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase","volume":"26","author":"Mousavi-Jazi","year":"2003","journal-title":"J.\u00a0Clin. Virol."},{"key":"10.1016\/j.antiviral.2016.12.003_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/prot.21005","article-title":"Three-dimensional modeling of cytomegalovirus DNA polymerase and preliminary analysis of drug resistance","volume":"64","author":"Shi","year":"2006","journal-title":"Proteins"},{"key":"10.1016\/j.antiviral.2016.12.003_bib19","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1128\/JCM.43.1.208-213.2005","article-title":"How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients","volume":"43","author":"Springer","year":"2005","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2016.12.003_bib20","first-page":"9530","article-title":"Distribution and effects of amino acid changes in drug-resistant alpha and beta herpesviruses DNA polymerase","volume":"44","author":"Topalis","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2016.12.003_bib21","doi-asserted-by":"crossref","first-page":"e1002905","DOI":"10.1371\/journal.ppat.1002905","article-title":"PDGF receptor-alpha does not promote HCMV entry into epithelial and endothelial cells but increased quantities stimulate entry by an abnormal pathway","volume":"8","author":"Vanarsdall","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2016.12.003_bib22","doi-asserted-by":"crossref","first-page":"25246","DOI":"10.1074\/jbc.M111.248864","article-title":"Phosphonoformic acid inhibits viral replication by trapping the closed form of the DNA polymerase","volume":"286","author":"Zahn","year":"2011","journal-title":"J.\u00a0Biol. Chem."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216306532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216306532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T16:18:42Z","timestamp":1657988322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354216306532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":22,"alternative-id":["S0166354216306532"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.12.003","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}